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1. Introduction 
Dermatomyositis (DM) and polymyositis (PM) are types of autoimmune inflammatory 
muscle disease that mainly damage proximal limb muscles, with DM involving 
characteristic skin findings such as Gottron's sign and heliotrope eruption (Bohan & Peter, 
1975a, 1975b). Interstitial pneumonia (IP) is often associated with DM/PM and is one of the 
important prognostic factors. Above all, rapidly progressive IP (RPIP), which has the worst 
prognosis, is resistant to corticosteroid drugs and is strongly associated with clinical 
amyopathic DM (CADM), which is unlikely to show myositis (Kameda & Takeuchi, 2006). 
In response, combination therapies of corticosteroid drugs and immunosuppressive drugs 
have recently been administered early in the onset of IP, and outcomes have been improved. 
Here, we review the pathogenesis, the clinical and laboratory findings, and treatment of IP 
associated with DM/PM. 
2. IP Associated with DM/PM 
IP occurs in association with DM/PM in 40-50% of patients and is an important prognostic 
factor of DM/PM (Hidano, 1992, Marie, 2002, Fathi, 2004). In 2002, the American Thoracic 
Society and the European Respiratory Society jointly advocated classifying idiopathic IP into 
7 types (American Thoracic Society & European Respiratory Society, 2002), which are 
applied to IP associated with connective tissue disease. Many cases of IP associated with 
DM/PM comprise one of 3 types: nonspecific interstitial pneumonia (NSIP), cryptogenic 
organizing pneumonia (COP), or diffuse alveolar damage (DAD) (Douglas, 2001, Fujisawa, 
2005). Prognoses vary according to these types: cases of DAD are the most critical, but some 
cases of NSIP and COP also progress to unfortunate outcomes. IP is classified according to 
clinical course into 1 of 3 groups: acute/subacute IP (A/SIP) with rapidly progression over 
several weeks or months, chronic IP (CIP) with slowly progression over years, and 
asymptomatic type with only minor abnormalities on chest CT or in respiratory function 
tests (Frazier & Miller, 1974). 
The histological features of muscle biopsies in DM and PM are different, as are the 
pathological features of the IP associated with each disease. PM mainly is associated with 
slowly progressive CIP, which histologically presents as fibrotic NSIP and which responds 
to corticosteroids. A/SIP also is associated with COP or cellular NSIP and shows good 
response to corticosteroids in many cases. In contrast, almost 50% of DM cases are 
associated with A/SIP, which histologically presents as fibrotic NSIP or DAD (Hirakata & 
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Nagai, 2000). It often evolves into corticosteroid-resistant RPIP, often progressing to acute or 
subacute disease in several weeks or months, and many patients die in spite of strong 
immunosuppressive therapies. There are many unclear points as to how certain cases evolve 
into RPIP. Some cases that were identified histologically as NSIP change to DAD. In 
addition, pathological findings can be mixed within the same patient, and the histological 
picture may vary according to the site of tissue sampling. 
3. Laboratory findings 
3.1 Pulmonary function tests 
Pulmonary function tests (PFT) provide objective evaluation of respiratory symptoms and 
are important in determining the disease activity and therapeutic effects. However, in 
patients with severe respiratory failure such as that in RPIP, the tests cannot be performed 
or the results are not determined. Typically, a restrictive ventilatory impairment is present, 
and total lung capacity (TLC), vital capacity (VC), forced vital capacity (FVC), and the 
diffusing capacity for carbon monoxide (DLco) are decreased (Fathi, 2008). A decrease in 
DLco is one of the most sensitive indices showing a decrease in gas exchange. These 
abnormalities are improved by treatment. In cases without IP but with decreased FVC, it is 
necessary to also consider a decrease in ventilatory muscle strength. 
3.2 Diagnostic Imaging 
For imaging assessment of IP, the sensitivity of the chest X-ray is lower than that of high-
resolution CT (HRCT) using less than 3-mm slices (Figure 1). When PM/DM or IP 
associated with PM/DM is suspected, the lung should be assessed by HRCT. However, 
because the chest X-ray is easy to use and radiation exposure is low, it is useful for following 
the course of the disease and for diagnosing complications such as infection. 
HRCT findings observed in PM/DM are diverse. The most frequently observed findings are 
reticular opacity or ground-glass opacity with subpleural curvilinear shadow that is 
predominantly distributed just below the bilateral dorsal regions of the lungs, and the 
findings sometimes accompany consolidation (Mino, 1997, Douglas, 2001, Arakawa, 2003, 
Bonnefoy, 2004, Hayashi, 2008). Ground-glass opacity and consolidation are improved by 
treatment. The decreased lung volume and traction bronchiectasis (TBE) are sometimes 
observed, but patients with honeycomb lung are rare. It is difficult to predict the prognosis 
of IP associated with DM/PM and to select treatment based only on HRCT findings. 
However, HRCT are useful for the assessment of disease activity and therapeutic effect. IP 
that is distributed through a wide area of the lungs and accompanies TBE at the early onset 
or exacerbation has a poor prognosis. 
3.3 Biomarkers of IP 
Autoantibodies to various cell components are detected in 50 to 80% of PM/DM patients 
(Reichlin & Arnett, 1984, Love 1991). Myositis-specific autoantibodies such as anti-aminoacyl 
transfer RNA synthetase (ARS) antibody and anti-signal recognition particle (SRP) antibody 
are specifically detected in PM/DM, and myositis-related antigens, such as anti-Ku 
antibody and anti-U1-RNP antibody, are also detected in connective tissue diseases other 
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Fig. 1. Chest HRCT of IP associated with DM. (A) ground-glass opacity (open arrow) and 
consolidation (arrow); (B) subpleural curvilinear shadow (arrow); (C) Traction bronchiectasis. 
than PM/DM. Patients from whom these autoantibodies are detected have respective 
clinical characteristics. Anti-ARS antibodies are detected in 25 to 30% of PM/DM patients, 
and of these anti-ARS antibodies, anti-Jo-1 antibody is most frequently detected and is 
closely related with myositis. Antibodies related to IP include anti-PL-12 antibody and anti-
KS antibody (Friedman, 1996, Hirakata, 2007). Patients who test positive for anti-SRP 
antibody are considered to have fewer complications from IP (Targoff, 1990). Patients with 
CADM frequently complicate RPIP with poor prognosis and have been found to frequently 
test negative for antinuclear antibody. Recently, anti-CADM-140 (mda-5) antibody has been 
detected in the serum of patients with CADM (Sato, 2005). In the future, if a relation 
between this antibody and pathogenesis/clinical presentation is revealed, selection of 
treatment and prognosis are expected to improve. 
Krebs von den Lungen-6 (KL-6) and surfactant D (SpD), which are produced and secreted 
on the epithelial surface by alveolar type II cells and bronchial epithelial cells, are useful 
markers for IP. These makers increase in the serum of patients with IP associated with 
PM/DM. The levels of these markers are inversely correlated with DLco and are useful in 
judging therapeutic effect (Kubo, 2000, Bandoh, 2000, Ihn, 2002). Not all patients with IP 
associated with PM/DM show increases in KL-6 and SpD, and there are patients without 
increased levels of KL-6 and SpD, especially in the acute phase. 
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Ferritin is the major molecule of iron storage, and it was reported that serum ferritin level 
increases in A/SIP associated with DM (Gono, 2010). Serum ferritin level is also useful as a 
predictive factor for onset of A/SIP and is related to its prognosis. Although it is not 
altogether clear why serum ferritin increases in A/SIP, it is considered to be related to 
activation of alveolar macrophages. 
4. Treatment of IP 
Therapy with massive doses of corticosteroids is used in the treatment of DM/PM-
complicated IP. Although it is often effective in PM, IP associated with DM, especially in the 
initial treatment of RPIP, is often refractory to corticosteroid therapy . Nawata et al. reported 
on the prognosis of the treatment of IP in 31 cases of DM/PM using corticosteroid drugs 
along with pulse therapy (Nawata, 1999). The first-year survival rate after beginning the 
treatment was 50% in 20 patients with DM and 90% in 11 patients with PM. In addition, in 
all patients who died, death occurred within 12 weeks and was due to an exacerbation of IP 
or infection. Fujisawa et al. reported initial survival rates in 12 patients with DM and 16 
patients with PM of 58% and 81%, respectively, when combining corticosteroids with an 
immunosuppressive agent such as cyclophosphamide (Fujisawa, 2005). 
The combination of corticosteroids with immunosuppressive agents is currently the 
preferred method of treatment of DM/PM-complicated IP, especially in the early treatment 
of RPIP. Nagasawa et al. surveyed 32 facilities nationwide that specialize in the treatment of 
connective tissue diseases. The group analyzed clinical data from 38 patients with acute IP 
in DM/PM who were treated for 2 or more weeks with cyclosporine (Nagasawa, 2003). 
Among 25 patients who were initially treated for 2 weeks or longer using only 
corticosteroids following the addition of cyclosporine, the 2-year survival rate was 32%. 
Among the other13 patients who were treated with cyclosporine within 2 weeks of starting 
corticosteroid treatment, the average survival rate 2 years later was 69%. Takada et al. 
reported that when comparing the results from 20 active cases of DM/PM-complicated IP, 
in which only additional immunosuppressive agents were added if corticosteroid alone did 
not result in a favorable response, with 14 additional cases in which immunosuppressive 
agents were combined with corticosteroids, the combination therapy led to a higher survival 
rate (Takada, 2007). Other clinical trials reported similar results (Yamasaki, 2007, Kotani, 
2008). These reports indicate that early combined therapy is more effective than combining 
additional agents at a later time; as a result, this maximizes the effectiveness of the 
immunosuppressant. 
4.1 Immunosuppressants available for DM/PM-complicated IP 
Currently, positive clinical trials are going forward for the following immunosuppressive 
drugs used in the treatment of DM/PM-complicated IP: cyclophosphamide, cyclosporine, 
and tacrolimus, amongst others. It is important to introduce treatment with the 
immunosuppressive agent at an early stage before remodeling the lung tissues, and the 
dosage and the mode of administration can also greatly influence the therapeutic effect. In 
addition, because of possible side effects, it is necessary to monitor renal function and 
carefully consider the dosages and effects of possible drug combinations. Specifically, 
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infectious diseases are a critical side effect of each type of medicine. As reported by Kameda 
et al. and Kotani et al., through careful monitoring and early detection of infection, 
preventative treatments can be administered at an early stage leading to a decreased 
number of deaths due to infectious diseases (Kamdeda 2006, Kotani, 2008). In our facility, 
factors such as leukocyte count (lymphocyte count), CRP, IgG, β-D-glucan, CMV-C7-HRP, 
procalcitonin, are regularly measured, and Trimethoprim-sulfamethoxazole is administered 
to prevent Pneumocystis jiroveci. 
4.2 Cyclosporine 
Cyclosporine is a metabolic product of fungi and a hydrophobic cyclic polypeptide. When it 
is incorporated into T-lymphocytes, it binds to cyclophilin to form a complex, and when this 
complex inhibits the activity of calcineurin, expression of cytokine genes such as IL-2 and 
early activation genes is down-regulated. In DM/PM-complicated IP, because involvement 
of T-lymphocytes has been suggested from the lung biopsy and lymphocyte subset analysis 
of bronchoalveolar lavage fluid, concomitant therapy with steroids and cyclosporine has 
been conducted and has been shown to be efficacious (Nawata, 1999, Nagasawa, 2003, 
Kameda, 2005, Kotani, 2008). However, these various reports indicate variability in 
therapeutic effect as the reported survival rates range from 42 to 78%. 
Cyclosporine is likely to be affected by food and the amount of bile acid secreted, and the 
absorbed amount of cyclosporine varies within and between individuals. Because the 
therapeutic efficacy of cyclosporine depends on the concentration of the drug in the body 
and not on the dose, therapeutic drug monitoring (TDM) to determine the method of 
administration based on the concentration of the drug in the blood of individual patients 
has been recommended. In the treatment of DM/PM-complicated IP, cyclosporine has 
been administered at doses between 100 and 300 g/day (3 to 5 mg/kg/day) and at a 
serum trough concentration (C0) between 150 and 250 ng/mL, but there are no specific 
guidelines. 
Recently, Nagai et al. conducted and reported on TDM in 15 IP patients complicated with 
DM to determine the optimal method of cyclosporine administration (Nagai, 2010). It is 
known from organ transplantation that the immunosuppressive effect of cyclosporine 
correlates best with the area under the blood concentration curve (AUC), but this is not so 
suitable for use in daily management because frequent blood sampling is required. 
Therefore, the concentration of cyclosporine in the blood was determined before and after 
administration to determine which concentration correlates best with the AUC. As a result, 
the blood concentration at 2 hours after administration (C2) was the highest among all the 
patients, correlated best with AUC, and was considered to be an index of 
immunosuppressive effect (Figure 2). However, C0 did not correlate with the AUC. 
Moreover, when comparing between two postprandial doses and one preprandial dose, 
there was no difference in C2, but C0 was significantly lower when cyclosporine was 
administered once daily breakfast (Figure 3). Because the incidence of adverse events with 
cyclosporine increases when cyclosporine is used for a long time at a C0 of 200 ng/mL or 
higher (Min, 1998), the utility of the administration of one preprandial dose has been 
reported. 
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Fig. 2. Correlation of AUC0-6 with C0, C2 and C4 of cyclosporine. C0 presents the serum 
trough concentration. C2 and C4 present the blood concentration at 2 and 4 hours after 
administration, respectively. Closed and Open circles represent patients with preprandial and 
postprandial administration, respectively. Reproduced with permission from Nagai K, et al., 
Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with 
dermatomyositis. Mod Rheumatol, 2010 (21): 32-36. 
 
Fig. 3. Comparison of blood cyclosporine level between postprandial daily administration in 
two doses and preprandial, once daily administration; Pre preprandial, once daily before 
breakfast in a single dose; Post postprandial, twice daily in a divided dose. Reproduced with 
permission from Nagai K, et al., Therapeutic drug monitoring of cyclosporine 
microemulsion in interstitial pneumonia with dermatomyositis. Mod Rheumatol, 2010 (21): 
32-36. 
Adverse events to cyclosporine include infection as well as renal disorders, hypertension, 
diabetes mellitus, and hepatic disorders. Because the onset of adverse events is 
concentration-dependent, the dose is adjusted so that the C0 is 200 ng/mL or less, but it may 
be impossible to reduce the dose because of the high activity of IP. Nagai et al. reported that 
when the C2 was 1222.6±523.8 ng/mL, the C0 was 157.3±41.4 ng/mL (Nagai, 2010), so 
cyclosporine can be used relatively safely if the C2 is maintained at about 1200 ng/mL. If 
cyclosporine is used for a long time, however, the serum creatinine value gradually 
increases. Thus, monitoring of both C2 and C0 are required for the assessment of 
immunosuppressive effects and adverse events. Moreover, because cyclosporine is 
metabolized at cytochrome P450 (CYP) 3A4, concomitant use with tacrolimus, bosentan, 
pitavastatin, and rosuvastatin is contraindicated, and it is also necessary to pay attention to 
concomitant use with aminoglycoside antibiotics and amphotericin B, which have been 
known to induce renal disorders. 
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It has been reported that the immunosuppressive effect of cyclosporine reaches its 
maximum effects if the C2 exceeds 1000 ng/mL. The ideal dose of cyclosporine in the 
treatment of DM/PM-complicated IP has not been established yet. The dose is reported to 
be variable, which may affect its therapeutic effect. In the future, it will be necessary to 
evaluate not only dosage and C0 but also C2. Recently, Kotani et al. reported that the C2 of 
cyclosporine correlated with the HRCT findings and improvement of respiratory function 
instead of C0 (Kotani, 2011). 
4.3 Tacrolimus 
Tacrolimus is a metabolic product of an actinobacteria, Streptomyces tsukubaensis, and has a 
macrolide skeleton. When it is incorporated into T-lymphocytes, it forms a complex with the 
FK506-binding protein. As a cyclosporine, this complex shows immunosuppressive effects 
by inhibiting the activity of calcineurin. The activity of tacrolimus is 30- to 100-times higher 
than that of cyclosporine in vitro, and it inhibits mixed lymphocyte culture reaction, 
production of IL-2, expression of IL-2 receptor, and production of IFN-γ. Clinically, 
tacrolimus is used for inhibition of rejection after transplantation of kidneys, liver, heart, 
lung and pancreas and in rheumatic diseases such as systemic lupus erythematosus, 
rheumatoid arthritis, Behçet’s disease, and myasthenia gravis. 
Oddis et al. reported the utility of tacrolimus in 8 patients with refractory PM associated 
with IP (Oddis, 1999). When tacrolimus was orally administered to maintain the C0 at 5 to 
20 ng/mL, recovery of muscle strength was observed in all 8 patients, and among 5 patients 
complicated with IP, 3 showed improvement, and 1 was stabilized. Thereafter, Wilkes et al. 
reported 13 patients with anti-tRNA synthase antibody-positive refractory DM/PM who 
were treated with tacrolimus (Wilkes, 2005). It was possible to rescue all the patients, to 
improve respiratory function, and to reduce the dose of corticosteroids administered. 
Takada et al. retrospectively examined the clinical effects of tacrolimus in 5 IP patients 
complicated with refractory DM/PM (Takada, 2005). As a result, they reported that all 5 
patients could be rescued and that in 4 patients who could be evaluated by PFT before and 
after treatment, the PFT values were improved. 
The treatment of DM/PM-complicated IP is conducted at a tacrolimus dose of 4 to 6 
mg/day and a C0 of 5 to 10 ng/mL. Tacrolimus is also likely to be affected by food, and it is 
known that the AUC and the maximum blood concentration (Cmax) decrease with 
postprandial administration. For cyclosporine, C2 monitoring is required to evaluate 
immunosuppressive effects, but for tacrolimus, since both the blood concentrations before 
and at 0 to 7 hours after administration correlate well with the AUC, it is better to monitor 
C0 only. (Figure 4) 
The adverse events of tacrolimus are infection as well as renal disorders, hypertension, 
diabetes mellitus, and hyperkalemia. The onset of adverse events depends on the 
concentration, and if the C0 is as high as 20 ng/mL for a long time, adverse reactions 
increase. Similar to cyclosporine, because tacrolimus is metabolized at CYP3A4, it is 
necessary to pay attention to concomitant drug use. Moreover, because hyperkalemia can be 
observed, attention must be paid to administration of potassium-conserving diuretics such 
as spironolactone and eplerenone. 
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Fig. 4. Correlation of AUC0-6 with C0, C2 and C4 of Tacrolimus. C0 presents the serum 
trough concentration. C2 and C4 present the blood concentration at 2 and 4 hours after 
administration, respectively. 
4.4 Cyclophosphamide 
Cyclophosphamide is an alkylating agent that is used to inhibit rejection after renal 
transplantation and for the treatment of malignant tumors. Cyclophosphamide itself has no 
alkylating effect, but many of its metabolites have activities that alkylate guanine and inhibit 
replication of DNA chains and transcription to mRNA. To exert their immunosuppressive 
effects, these metabolites inhibit differentiation and proliferation of T-cells and B-cells and 
suppress antigen processes of antigen-presenting cells such as macrophages. 
DM/PM-complicated IP is treated by pulse intravenous infusion of cyclophosphamide (IV-
CY, 500 to 2,000 mg) in combination with corticosteroids. In the initial case reports, the 
effects of IV-CY were variable. Yamasaki et al. administered IV-CY at doses of 300 to 800 
mg/m2 6 times every 4 weeks in addition to steroids to 17 patients with DM/PM-
complicated IP (Yamasaki, 2007). Dyspnea improved in 11 patients, %VC improved by 10% 
or more in 8 patients, and the chest CT score improved in 9 patients. Moreover, the number 
of days from the start of initial treatment and the rate of improvement in %VC showed a 
negative correlation, indicating the utility of early concomitant treatment. 
Cyclophosphamide exerts strong immunosuppressive effects but is also accompanied by a 
number of adverse events including myelosuppression and following infections, 
hemorrhagic cystitis, ovarian insufficiency, azoospermia, and secondary carcinogenesis. It is 
therefore problematic whether cyclophosphamide may be used continuously for a long time 
in relapsed patients after remission induction or in patients with chronic advanced disease. 
It is considered useful to conduct initial treatment with concomitant use of corticosteroids 
and cyclophosphamide and then to switch to other immunosuppressive drugs, but this 
requires further evaluation. A prospective comparative study in which corticosteroids and 
IV-CY were administered 6 times every 4 weeks and then switched to azathioprine (2.5 
mg/kg/day) was conducted in IP patients complicated with scleroderma17), which may be 
helpful for the treatment of DM/PM-complicated IP. 
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5. Conclusion 
There are limitations in the treatment of DM/PM-complicated IP, and particularly RRIP, 
with corticosteroids alone; thus, immunosuppressive drugs should be introduced early and 
aggressively before remodeling of the lung tissues. Many challenges remain in determining 
what treatment should be started for which patient, how to perform maintenance therapy, 
and how to switch between immunosuppressive drugs. At this time, prospective clinical 
studies of various immunosuppressive drugs are ongoing, and the results are eagerly 
anticipated. 
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